Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients

On Tuesday, Pliant Therapeutics Inc announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF) characterized by excessive collagen deposition in the lung.